Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px
Document › Details

Merck KGaA. (1/13/22). "Press Release: Merck Announces New Appointments in Global R&D and Strategy Leadership for Healthcare Business Sector". Darmstadt.

Region Region ALL
Organisations Organisation Merck (DE) (Group)
  Organisation 2 Novartis AG (NYSE: NVS)
  Group Novartis (Group)
Products Product pharmaceutical
  Product 2 drug development
Persons Person Bar-Zohar, Danny (Merck (DE) 202112 Head of Global Developm Biopharma before Syncona + Novartis + Teva)
  Person 2 Halle, Jörn-Peter (Merck (DE) 202110 Head of Global Research at Healthcare Business Sector)

Merck, a leading science and technology company, today announced new appointments in Global R&D and Strategy leadership for the Healthcare business sector. Danny Bar-Zohar, MD, will become Global Head of R&D and Joern-Peter Halle, PhD, will become Chief Strategy Officer.

“At the critical intersection of R&D and Strategy is a very unique opportunity to make bold choices that best position us to deliver on our fullest innovative potential for patients and for Merck,” said Peter Guenter, Member of the Executive Board of Merck, and CEO Healthcare. “With Danny and Joern-Peter, we have the perfect combination of collaboration, strategic vision and leadership, in addition to world-class experience and expertise, to move beyond the status quo and lead our innovation engine for today and for the future.”

As Global Head of R&D, Bar-Zohar will lead Research and Development, including Medical Affairs. Bar-Zohar joined Merck in November 2020 as Executive Vice President, Global Head of Development. He has more than a decade of leadership experience in pharma, having worked previously at Novartis and Teva. He brings global drug development experience from strategy to execution to this position, across almost every modality in drug development, including small molecules, therapeutic proteins, antibodies and gene therapy. Bar-Zohar’s proven track record will serve to further advance the highly innovative and differentiated early-stage assets the Merck research teams have delivered into development in recent years.

As Chief Strategy Officer, Halle will lead Strategy and Business Development. Halle brings significant experience to this role, having previously served as Executive Vice President, Global Head of Research for the last 18 months, leading discovery through pre-clinical efforts for the company’s Oncology/Immuno-Oncology and Immunology therapeutic areas. Halle also served as Senior Vice President, Head of Immuno-Oncology research, and Senior Vice President, Head of External Innovation. Halle brings more than 25 years of industry experience to this position. He joined Merck in 2005.

Both Bar-Zohar and Halle will continue to be part of the Healthcare Executive Committee and be based at the company’s global headquarters in Darmstadt, Germany.

For more information, please contact Gangolf Schrimpf
+49 151 1454-9591

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Record changed: 2022-09-19


Picture Campus Berlin-Buch GmbH GMP Basic Course Online 650x200px

More documents for Merck (DE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top